gm237354 has been researched along with Candidiasis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviles, P; Falcoz, C; Gargallo-Viola, D; San Roman, R | 1 |
| Aviles, P; Falcoz, C; Gargallo-Viola, D; Gómez De Las Heras, F; Guillén, MJ; San Roman, R | 1 |
2 other study(ies) available for gm237354 and Candidiasis
| Article | Year |
|---|---|
Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis.
Topics: Animals; Antifungal Agents; Area Under Curve; Candida albicans; Candidiasis; Disease Models, Animal; Indenes; Male; Mice; Microbial Sensitivity Tests; Statistics as Topic; Treatment Outcome | 2000 |
Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.
Topics: Animals; Antifungal Agents; Binding Sites; Blood Proteins; Candida albicans; Candidiasis; Disease Models, Animal; Indenes; Male; Mice; Microbial Sensitivity Tests; Models, Biological; Statistics as Topic; Treatment Outcome | 2001 |